Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580351 | 1.00 | TSHR (0.56) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL9439905 | 1.00 | TSHR (0.56) | TSHRPGDHTTCYP2C9PDE4A | |
| Water SCHEMBL28238706 | 0.97 | TSHR (0.53) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL14742965 | 0.97 | TSHR (0.59) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL1397720 | 0.94 | TSHR (0.62) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL29232003 | 0.94 | TSHR (0.62) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL9862728 | 0.94 | TSHR (0.62) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL10629208 | 0.92 | TSHR (0.53) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL22609753 | 0.90 | TSHR (0.50) | TSHRPGDHTTCYP2C9PDE4A | |
| SCHEMBL27476046 | 0.90 | TSHR (0.50) | TSHRPGDHTTCYP2C9PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6162464-A | Non-aqueous colonic purgative formulations | INKINE PHARMACEUTICAL, INC. (US) | 2000-12-19 | — | — | US | claimed |
| EP-4302767-B1 | OPHTHALMIC COMPOSITION COMPRISING ERIOCITRIN FOR TREATING DRY EYE SYNDROME | SKEYE PHARMA GMBH (DE) | 2024-10-02 | — | — | EP | disclosed |
| EP-4355298-A1 | OPHTHALMIC COMPOSITION COMPRISING XANTHOHUMOL | Skeye Pharma GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| EP-4302767-A1 | OPHTHALMIC COMPOSITION COMPRISING ERIOCITRIN | Skeye Pharma GmbH (DE) | 2024-01-10 | — | — | EP | disclosed |
| US-11672798-B2 | Ciprofloxacin ophthalmic topical composition for treating ocular disease | LABORATORIOS SALVAT, S.A. (ES) | 2023-06-13 | — | — | US | disclosed |
| EP-3720428-B1 | OPHTHALMIC TOPICAL COMPOSITION COMPRISNG DOBESILIC ACID FOR TREATING DISEASES OF THE POSTERIOR SEGMENT OF THE EYE | SALVAT LAB SA (ES) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022263286-A1 | OPHTHALMIC COMPOSITION COMPRISING XANTHOHUMOL | SKEYE PHARMA GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104818-A1 | OPHTHALMIC COMPOSITION COMPRISING XANTHOHUMOL | Skeye Pharma GbR (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4104817-A1 | OPHTHALMIC COMPOSITION COMPRISING ASTRAGALOSIDE IV | Skeye Pharma GbR (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022253970-A1 | CIPROFLOXACIN OPHTHALMIC TOPICAL COMPOSITION FOR TREATING OCULAR DISEASE | LABORATORIOS SALVAT, S.A. (ES) | 2022-12-08 | — | — | WO | disclosed |
| US-10857160-B2 | Oil-in-water nanoemulsion composition of clobetasol | LABORATORIOS SALVAT, S.A. (ES) | 2020-12-08 | — | — | US | disclosed |
| EP-3720428-A1 | OPHTHALMIC TOPICAL COMPOSITION COMPRISING DOBESILIC ACID FOR TREATING DISEASES OF THE POSTERIOR SEGMENT OF THE EYE | Laboratorios SALVAT, S.A. (ES) | 2020-10-14 | — | — | EP | disclosed |
| US-10660848-B2 | Ophthalmic compositions | LABORATORIOS SALVAT, S.A. (ES) | 2020-05-26 | — | — | US | disclosed |
| EP-3641728-A1 | AN OIL-IN-WATER NANOEMULSION COMPOSITION OF CLOBETASOL | Laboratorios SALVAT, S.A. (ES) | 2020-04-29 | — | — | EP | disclosed |
| US-20190298737-A1 | AN OIL-IN-WATER NANOEMULSION COMPOSITION OF CLOBETASOL | LABORATORIOS SALVAT, S.A. (ES) | 2019-10-03 | — | — | US | disclosed |
| WO-2019110416-A1 | OPHTHALMIC TOPICAL COMPOSITION COMPRISING DOBESILIC ACID FOR TREATING DISEASES OF THE POSTERIOR SEGMENT OF THE EYE | LABORATORIOS SALVAT, S.A. (ES) | 2019-06-13 | — | — | WO | disclosed |
| WO-2018233878-A1 | AN OIL-IN-WATER NANOEMULSION COMPOSITION OF CLOBETASOL | LABORATORIOS SALVAT, S.A. (ES) | 2018-12-27 | — | — | WO | disclosed |
| EP-3266446-B1 | OPHTHALMIC COMPOSITION COMPRISING CASTOR OIL AND MEDIUM CHAIN TRIGLYCERIDE | SALVAT LAB SA (ES) | 2018-11-21 | — | — | EP | disclosed |
| US-20180008538-A1 | OPHTHALMIC COMPOSITIONS | LABORATORIOS SALVAT, S.A. (ES) | 2018-01-11 | — | — | US | disclosed |
| EP-3266446-A1 | OPHTHALMIC COMPOSITION COMPRISING CASTOR OIL AND MEDIUM CHAIN TRIGLYCERIDE | Laboratorios SALVAT, S.A. (ES) | 2018-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857160-B2 | Oil-in-water nanoemulsion composition of clobetasol | APOB, TNF, CLTB | TSHR 2218/4885PGD 4657/4885HTT 1949/4885 |
| US-11672798-B2 | Ciprofloxacin ophthalmic topical composition for treating ocular disease | PDE6C, ABCB11, EYA3 | TSHR 4377/4885PGD 2932/4885HTT 2683/4885 |
| US-20190298737-A1 | AN OIL-IN-WATER NANOEMULSION COMPOSITION OF CLOBETASOL | APOB, TNF, CLTB | TSHR 2523/4885PGD 4615/4885HTT 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.